金河生物(002688.SZ)上半年營收增18.5%至8.34億元
格隆匯8月23日丨金河生物(002688.SZ)公佈2019上半年業績，公司實現營業收入8.34億元，比上年同期增加18.50%；實現營業利潤1.31億元，同比增加29.04%；歸屬於上市公司股東的淨利潤為1.05億元，同比增加23.31%。
飼料添加劑業務：報告期內，美國市場產品銷售大幅增長，國內市場由於環保趨嚴導致部分獸藥生產企業產能受限以及農業部對部分抗生素產品停止使用，金黴素產品價格較去年同期上漲。飼料添加劑業務在境外的迅速回暖帶動公司整體銷售業績比上年同期上升。本報告期飼料添加劑業務實現銷售收入5.06億元，比上年同期增加6929.58萬元，增幅15.88%。
獸用疫苗業務：公司疫苗產品目前以豬用疫苗為主，受非洲豬瘟疫情的影響，生豬存欄量鋭減，下游需求減少，銷售疲軟。本報告期獸用疫苗實現銷售收入3513.50萬元，比上年同期減少2964.79萬元，減幅45.77%。報告期內，公司在新產品儲備方面做了大量的工作，豬丹毒滅活疫苗、豬繁殖與呼吸綜合徵嵌合病毒活疫苗（PC株）於近期取得獸藥產品批准文號，豬繁殖&呼吸綜合症疫苗（簡稱PRRSV疫苗，豬藍耳病嵌合疫苗）報告期內取得了美國農業部頒發的獸用生物製品許可證。豬支原體-豬圓環病毒Ⅱ型二聯疫苗進口註冊申請工作正在積極推進。
獸用化學藥品業務：同樣受非洲豬瘟疫情的影響，獸用化學藥品業務也受到一定的衝擊。本報告期繼續積極拓展市場，調整產品結構。本報告期獸用化學藥品業務實現銷售收入1189.44萬元，比上年同期增加304.23萬元，增幅34.37%。
農產品加工業務：本期受下游市場需求擴大影響，產能進一步釋放，銷售價格比上年同期也有所上升。本報告期農產品加工業務實現營業收入2.17億元，比上年同期增加5809.94萬元，增幅36.64%。
環保業務：金河環保公司業務發展穩定，污水處理量不斷增加。公司在業務向外拓展方面進行了積極的探索，為今後的持續穩定發展奠定了基礎。扎旗水務的運營對本報告期業績提升做出了貢獻。本報告期環保業務實現營業收入3666.87萬元，比上年同期增加1200.27萬元，增幅48.66%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
